micronucleus assay for evaluation of genotoxicity in potentially malignant and malignant disorders
Clicks: 233
ID: 157332
2011
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
225 views
15 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Oral cancer is a common malignancy, ranking first among all cancers in Western and Asian countries. It is preceded by some benign lesions or conditions, which are termed precancerous. Only one-third of people at the precancerous stage of disease succumb to cancer, it would be of practical importance to identify individuals at risk among them. Biomarkers, instruments of individual tumor prevention, help to detect high-risk patents. The induction of micronucleus is considered to bean effective biomarker of diseases- In the recent past, a great deal of enthusiasm was raised by application of the micronucleus test to assess DNA damage in human population. The present study is aimed at the evaluation of frequency of micronuclei in smears of oral exfoliated cells. A total of 33 patients with potentially malignant (leukoplakia, OSMF, lichen planus) and malignant oral epithelial diseases from the department of oral medicine and radiology were considered as study group and compared with 33 age and sex matched healthy controls. Micronucleus frequencies were found higher in diseased patients than in control subjects- Hence, concluded that the micronucleus assay can be used as a prognostic indicator in potentially malignant and malignant disorders.
| Reference Key |
devi2011journalmicronucleus
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Parvathi Devi;V B Thimmarasa;Vishal Mehrotra;Pallak Arora |
| Journal | history of psychiatry |
| Year | 2011 |
| DOI |
10.5005/jp-journals-10011-1103
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.